Compare Eli Lilly And Co (LLY) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs TORM plc — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while TORM plc trades at $39.81 (market cap $4.12B). The key difference: Eli Lilly And Co is far larger — about 252.4× TORM plc's market cap, and TORM plc pays the higher dividend (11.03%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and TORM plc for 23 Days on average.
| LLY | TRMD | |
|---|---|---|
Market Cap | $1.04T | $4.12B |
Volume | 3,064,878 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $1.28K | $41.05 |
52-Week Low | $799.57 | $19.39 |
Typical Hold Time | 93 Days | 23 Days |
Enterprise Value | $1.09T | $4.83B |
Dividend Yield | 0.59% | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
TRMD trades at $40.19, up 3.26% today, with a bullish technical outlook from moving averages. The stock shows strong profitability with a 35.52% net income margin and attractive valuation ratios, including a P/E of 6.59. Recent earnings saw a Q4 2025 beat but Q1 and Q2 2026 misses, while Q3 2026 results are pending. A $2.40 dividend is scheduled for September 2026. Cash flow improved to a net positive $6M in 2026 from a negative $113.8M in 2025.
The outlook is positive given robust fundamentals and unanimous analyst buy ratings, though risks include spot rate volatility and insider selling. Revenue growth and dividend yield present opportunities, but investors should monitor freight rate trends and execution on future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
